Agios Pharmaceuticals Inc.

22.57+1.29+6.06%Vol 1.28M1Y Perf -62.40%
Jun 24th, 2022 16:00 DELAYED
BID17.10 ASK22.63
Open21.60 Previous Close21.28
Pre-Market- After-Market22.35
 - -  -0.22 -0.97%
Target Price
34.50 
Analyst Rating
Hold 2.71
Potential %
52.86 
Finscreener Ranking
★★     46.41
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★★★+     57.78
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★+     47.12
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
13.90 
Earnings Rating
Strong Buy
Market Cap1.24B 
Earnings Date
4th Aug 2022
Alpha-0.02 Standard Deviation0.14
Beta1.52 

Today's Price Range

21.0522.61

52W Range

16.7558.61

5 Year PE Ratio Range

-7.80-8.30

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
25.60%
1 Month
14.98%
3 Months
-21.60%
6 Months
-37.01%
1 Year
-62.40%
3 Years
-54.49%
5 Years
-61.86%
10 Years
-

TickerPriceChg.Chg.%
AGIO22.571.29006.06
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
20.30
21.30
0.06
0.08
-55.60
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
59.30
-46 676.20
-45 565.70
-353.90
-
RevenueValueIndustryS&P 500US Markets
832.00K
0.02
-4.52
16.20
Earnings HistoryEstimateReportedSurprise %
Q01 2022-1.85-1.745.95
Q04 2021-1.71-1.81-5.85
Q03 2021-1.61-1.488.07
Q02 2021-1.39-1.362.16
Q01 2021-1.23-1.31-6.50
Q04 2020-1.41-1.410.00
Q03 2020-1.40-1.43-2.14
Q02 2020-1.42-1.317.75
Earnings Per EndEstimateRevision %Trend
6/2022 QR-1.786.81Positive
9/2022 QR-1.778.76Positive
12/2022 FY-7.024.49Positive
12/2023 FY-6.4412.02Positive
Next Report Date4th Aug 2022
Estimated EPS Next Report-1.78
Estimates Count5
EPS Growth Next 5 Years %7.30
Volume Overview
Volume1.28M
Shares Outstanding54.79K
Shares Float48.55M
Trades Count16.53K
Dollar Volume28.29M
Avg. Volume1.04M
Avg. Weekly Volume1.65M
Avg. Monthly Volume810.00K
Avg. Quarterly Volume659.76K

Agios Pharmaceuticals Inc. (NASDAQ: AGIO) stock closed at 22.57 per share at the end of the most recent trading day (a 6.06% change compared to the prior day closing price) with a volume of 1.28M shares and market capitalization of 1.24B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 562 people. Agios Pharmaceuticals Inc. CEO is Jacqualyn A. Fouse.

The one-year performance of Agios Pharmaceuticals Inc. stock is -62.4%, while year-to-date (YTD) performance is -31.34%. AGIO stock has a five-year performance of -61.86%. Its 52-week range is between 16.75 and 58.61, which gives AGIO stock a 52-week price range ratio of 13.90%

Agios Pharmaceuticals Inc. currently has a PE ratio of -3.40, a price-to-book (PB) ratio of 0.82, a price-to-sale (PS) ratio of 1 183.36, a price to cashflow ratio of 50.40, a PEG ratio of 2.32, a ROA of -19.77%, a ROC of -19.75% and a ROE of -21.59%. The company’s profit margin is -%, its EBITDA margin is -45 565.70%, and its revenue ttm is $832.00 Thousand , which makes it $0.02 revenue per share.

Of the last four earnings reports from Agios Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.78 for the next earnings report. Agios Pharmaceuticals Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Agios Pharmaceuticals Inc. is Hold (2.71), with a target price of $34.5, which is +52.86% compared to the current price. The earnings rating for Agios Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Agios Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Agios Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.91, ATR14 : 1.42, CCI20 : 238.37, Chaikin Money Flow : 0.03, MACD : -0.43, Money Flow Index : 72.22, ROC : 15.45, RSI : 61.28, STOCH (14,3) : 99.32, STOCH RSI : 1.00, UO : 61.44, Williams %R : -0.68), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Agios Pharmaceuticals Inc. in the last 12-months were: Bruce Car (Option Excercise at a value of $0), David P. Schenkein (Option Excercise at a value of $0), David T. Scadden (Option Excercise at a value of $0), Ian T. Clark (Option Excercise at a value of $0), Jacqualyn A. Fouse (Option Excercise at a value of $0), James William Burns (Option Excercise at a value of $0), John M. Maraganore (Option Excercise at a value of $0), Jonathan Biller (Option Excercise at a value of $0), Kaye Foster (Option Excercise at a value of $0), Maykin Ho (Option Excercise at a value of $0), Paul J. Clancy (Option Excercise at a value of $0), Richa Poddar (Option Excercise at a value of $0), Sarah Gheuens (Option Excercise at a value of $0), T. J. Washburn (Option Excercise at a value of $0), T. J. Washburn (Sold 845 shares of value $26 169 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (28.57 %)
2 (33.33 %)
4 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (57.14 %)
4 (66.67 %)
4 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (14.29 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
2.71
Moderate Buy
2.33
Moderate Buy
2.00

Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

CEO: Jacqualyn A. Fouse

Telephone: +1 617 649-8600

Address: 88 Sidney Street, Cambridge 02139, MA, US

Number of employees: 562

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

66%34%

Bearish Bullish

67%33%

TipRanks News for AGIO

Tue, 17 May 2022 12:42 GMT Agios Pharma (AGIO) Receives a Hold from SVB Securities

- TipRanks. All rights reserved.

Tue, 15 Feb 2022 09:33 GMT Agios Pharma (AGIO) Gets a Hold Rating from Leerink Partners

- TipRanks. All rights reserved.

News

Stocktwits